Results 171 to 180 of about 14,094 (223)

The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults.

J Clin Endocrinol Metab
Lunati ME, Cimino V, Bernasconi D, Romano C, Disoteo O, Rossi A, Tinari C, Fiorina RM, Gandolfi A, Morpurgo PS, D'Addio F, Lazzaroni E, Losurdo F, Pastore I, Molteni L, Berra C, Ben Nasr M, Montefusco L, Bucciarelli L, Fiorina P.   +19 more
europepmc   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons, Husam Ghanim, James G. Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A. Batra, Robert S. Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R. Petrie, Paresh Dandona   +11 more
wiley   +1 more source

Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Al-Jarshawi M, Cole A, Bagur R, Wang HY, Ng CH, Yu D, Chew NWS, Mamas MA.   +7 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. Materials and Methods This retrospective cohort study compared 142 adults with type 1 diabetes (BMI ≥ 30 kg/m2) initiated on tirzepatide against 50 age‐, sex‐ and BMI‐matched ...
Simon A. Berry, Iona R. Goodman, Eleanor McNally, Jackie Elliott, Ahmed Iqbal   +4 more
wiley   +1 more source

Cross-sectional analysis of the reliability and engagement metrics of YouTube videos on semaglutide for weight loss. [PDF]

Medicine (Baltimore)
Güler Sönmez T, Fidanci İ.
europepmc   +1 more source

Not All Weight Loss Is Equal: Towards Muscle-Preserving Therapies in Obesity. [PDF]

J Cachexia Sarcopenia Muscle
Abraham JD, Khan MS, Anker SD.
europepmc   +1 more source

Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim In December 2022, semaglutide injections for weight management were marketed in Denmark. Pre‐marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed. This study aimed to describe real‐world use of semaglutide, including dose titration, discontinuation patterns and ...
Mie Dyberg Skandov, Katrine McLain Christensen, Dagmar Abelone Dalin, Janne Unkerskov, Andreas Brønden, Marie Lund, Mikkel Bring Christensen, Kristian Karstoft   +7 more
wiley   +1 more source

Semaglutide-induced lean mass loss: clinical concern or physiological adaptation. [PDF]

Ann Med Surg (Lond)
Qaseem M, Ahmad N, Haider E, Hasan AH.
europepmc   +1 more source

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Lykke Ida Kaas Oldenburg, Sine Pfeiffer Haugaard, Tobias Karlsson, Victoria Kegel‐Hübner, Mahera Parwez, Christoffer Wiingaard, Anne Flint   +6 more
wiley   +1 more source

The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials. [PDF]

BJPsych Open
Trott M, Arnautovska U, Johnston D, Ritchie G, Siskind D.   +4 more
europepmc   +1 more source